CHOptimax™, our proprietary technology, is well-protected by 61 issued patents, and 22 more applications are still in review. The clinical data of our pipeline produced by CHOptimax™ have demonstrated our new drug is safe, has low-immunogenicity, and exhibits other unique properties. Moreover, we have applied CHOptimax™ in making antibody-drug conjugates, and our synthesis process is already ahead of the leading competitor in the industry. CHO PHARMA has been expanding our business development team and looking forward to participate international BIO Conventions for technology licensing meetings. The first stage is upcoming BIO KOREA 2023 from May 10th to 12th in Seoul.

https://www.biokorea.org/program/business_01.asp